1. Home
  2. RHI vs CELC Comparison

RHI vs CELC Comparison

Compare RHI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

N/A

Current Price

$41.90

Market Cap

4.3B

ML Signal

N/A

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$64.15

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RHI
CELC
Founded
1948
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.2B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
RHI
CELC
Price
$41.90
$64.15
Analyst Decision
Hold
Strong Buy
Analyst Count
11
13
Target Price
$39.56
★ $150.85
AVG Volume (30 Days)
★ 2.0M
1.2M
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 5.62%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.90
N/A
Revenue
★ $5,378,506,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.95
$1,921.71
P/E Ratio
$46.59
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$21.83
$53.54
52 Week High
$47.14
$151.02

Technical Indicators

Market Signals
Indicator
RHI
CELC
Relative Strength Index (RSI) 54.08 42.83
Support Level $35.08 $53.54
Resistance Level $42.25 $73.29
Average True Range (ATR) 1.58 4.12
MACD -0.19 0.27
Stochastic Oscillator 17.03 25.58

Price Performance

Historical Comparison
RHI
CELC

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: